Outcomes	O

The	O
primary	O
outcome	O
was	O
28	B-TimeFrame
-	I-TimeFrame
day	I-TimeFrame
mortality	B-PrimaryOutcome
.	O

Secondary	O
endpoints	O
included	O
early	B-SecondaryOutcome
mortality	I-SecondaryOutcome
(	O
Days	B-TimeFrame
7	I-TimeFrame
and	I-TimeFrame
14	I-TimeFrame
)	O
,	O
the	O
need	B-SecondaryOutcome
for	I-SecondaryOutcome
orotracheal	I-SecondaryOutcome
intubation	I-SecondaryOutcome
by	B-TimeFrame
Day	I-TimeFrame
7	I-TimeFrame
,	O
and	O
the	O
proportion	B-SecondaryOutcome
of	I-SecondaryOutcome
patients	I-SecondaryOutcome
with	I-SecondaryOutcome
an	I-SecondaryOutcome
oxygenation	I-SecondaryOutcome
index	I-SecondaryOutcome
(	I-SecondaryOutcome
PaO2	I-SecondaryOutcome
/	I-SecondaryOutcome
FiO2	I-SecondaryOutcome
)	I-SecondaryOutcome
<	I-SecondaryOutcome
100	I-SecondaryOutcome
by	B-TimeFrame
Day	I-TimeFrame
7	I-TimeFrame
.	O

Post	O
hoc	O
exploratory	O
analyses	O
were	O
for	O
mortality	O
rates	O
in	O
subgroups	O
(	O
whether	O
enrolled	O
already	O
in	O
IMV	O
or	O
not	O
,	O
age	O
,	O
and	O
some	O
laboratorial	O
predictors	O
of	O
severity	O
)	O
.	O

Subgroup	O
analyses	O
were	O
based	O
on	O
the	O
same	O
direction	O
of	O
prespecified	O
hypotheses	O
(	O
benefit	O
of	O
MP	O
)	O
,	O
consistency	O
across	O
other	O
studies	O
,	O
and	O
a	O
strong	O
preexisting	O
biological	O
rationale	O
supporting	O
the	O
apparent	O
subgroup	O
effect	O
[	O
18	O
]	O
.	O

We	O
also	O
analyzed	O
the	O
length	B-OtherOutcome
of	I-OtherOutcome
hospitalization	I-OtherOutcome
,	O
the	O
radiological	B-OtherOutcome
presence	I-OtherOutcome
of	I-OtherOutcome
fibrosis	I-OtherOutcome
or	I-OtherOutcome
Bronchiolitis	I-OtherOutcome
Obliterans	I-OtherOutcome
with	I-OtherOutcome
Organizing	I-OtherOutcome
Pneumonia	I-OtherOutcome
(	I-OtherOutcome
BOOP	I-OtherOutcome
)	I-OtherOutcome
after	B-TimeFrame
Day	I-TimeFrame
7	I-TimeFrame
[	O
19	O
]	O
,	O
a	O
need	B-OtherOutcome
for	I-OtherOutcome
insulin	I-OtherOutcome
or	I-OtherOutcome
an	I-OtherOutcome
increase	I-OtherOutcome
in	I-OtherOutcome
the	I-OtherOutcome
dosage	I-OtherOutcome
in	I-OtherOutcome
diabetic	I-OtherOutcome
patients	I-OtherOutcome
,	O
a	B-OtherOutcome
positive	I-OtherOutcome
blood	I-OtherOutcome
culture	I-OtherOutcome
(	I-OtherOutcome
Bactec	I-OtherOutcome
)	I-OtherOutcome
,	O
and	O
the	O
presence	B-OtherOutcome
of	I-OtherOutcome
viral	I-OtherOutcome
RNA	I-OtherOutcome
in	I-OtherOutcome
the	I-OtherOutcome
naso	I-OtherOutcome
-	I-OtherOutcome
/	I-OtherOutcome
oropharyngeal	I-OtherOutcome
swab	I-OtherOutcome
at	B-TimeFrame
Day	I-TimeFrame
7	I-TimeFrame
.	O

As	O
per	O
protocol	O
,	O
the	O
Day	O
120	O
visit	O
will	O
focus	O
on	O
the	O
respiratory	O
sequelae	O
of	O
surviving	O
patients	O
;	O
therefore	O
,	O
those	O
data	O
will	O
not	O
be	O
presented	O
here	O
.	O

